Bio Plus Co (099430) Fair Value & Analysis
Healthcare · KR · Market cap 222B KRW
Fair value as of: Jul 20, 2026
From 14 valuation models · updated 21 days ago
Share price −7.0% over the past month.
Below-average quality, screening 11% undervalued on our models.
What matters now
- Our model range runs from 3,108 KRW (bear) to 5,180 KRW (bull), base 4,144 KRW. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 41/100 (below-average quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
58‑month range 3,310 KRW – 8,624 KRW · fair‑value band 3,108 KRW – 5,180 KRW · the 3,720 KRW price screens below the 4,144 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 20, 2026.
Analysis
Bio Plus Co (099430) currently trades at 3,720 KRW, while our model-based Fair Value estimate is 4,144 KRW, implying the stock looks roughly 11.4% undervalued today. The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Bio Plus Co generated revenue of 94.4B KRW at a net margin of 14.8%. Revenue grew 15.4% year over year. It earns a return on equity of 10.6%. Net debt stands at 38.2B KRW. Fundamentals as of Jul 20, 2026
Our scenario range runs from 3,108 KRW (bear case) to 5,180 KRW (bull case); at 3,720 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 55% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 11%, 099430 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Growth Earnings (10,554 KRW) versus Asset-Based (1,904 KRW). Highest evidence: Residual Income (76).
Notify me when 099430 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 44 · Market factors (momentum, volatility) 18
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus " Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names.
Full company description
Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus " Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names. The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms. In addition, it offers mesotherapy products, such as skin rejuvenation products under the Kiara Reju name; Slim Slimmer, a lipolysis solution; LumiDew, a whitening solution; JuveniHill, an anti-wrinkle solution; and hair scalp care, hair treatment, hair nutrition solutions under the BelloHa and BellaChe names, as well as cosmetics comprising heparinoid essence, EGF ball, and skin care gel under the La Bella name. The company was founded in 2003 and is based in Seongnam-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Bio Plus Co reported revenue of 90.9B KRW in FY2025 versus 37.4B KRW in FY2021, a compound +24.8%/yr. Reported net income was 15.0B KRW in FY2025, compounding +8.9%/yr from FY2021.
Watch 099430: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 35/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Bio Plus Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Bio Plus Co (099430) overvalued or undervalued?
What is the fair value of 099430?
What is the quality score of 099430?
What is the revenue of Bio Plus Co (099430)?
What is the net profit margin of 099430?
Does Bio Plus Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Bio Plus Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.